NEW YORK - A Cowen and Co. analyst initiated or revised coverage on several biotechnology stocks Wednesday.
Analyst Rachel McMinn downgraded Exton, Pa.-based Viropharma Inc. to "Neutral" from "Outperform", citing the company's pipeline. Its gastrointestinal tract infection treatment Vancocin could face generic competition as early as 2008, she said, and investors are taking a wait-and-see approach on results from the company's developing hepatitis C treatment.
read more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment